245 related articles for article (PubMed ID: 37317978)
21. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
[TBL] [Abstract][Full Text] [Related]
22. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
[TBL] [Abstract][Full Text] [Related]
23. Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.
Shi Y; Xue Y; Wang C; Yu L
Hematology; 2022 Dec; 27(1):609-619. PubMed ID: 35621728
[TBL] [Abstract][Full Text] [Related]
24. Nucleophosmin mutation in de-novo acute myeloid leukemia.
Rastogi P; Naseem S; Varma N; Varma S
Asia Pac J Clin Oncol; 2016 Mar; 12(1):77-85. PubMed ID: 26669619
[TBL] [Abstract][Full Text] [Related]
25. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
[TBL] [Abstract][Full Text] [Related]
26. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
28. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
29. Overlapping features of therapy-related and de novo NPM1-mutated AML.
Othman J; Meggendorfer M; Tiacci E; Thiede C; Schlenk R; Dillon R; Stasik S; Venanzi A; Bertoli S; Delabesse E; Dumas PY; Pigneux A; Bidet A; Gilkes AF; Thomas I; Voso MT; Rambaldi A; Brunetti L; Perriello VM; Andresen V; Gjertsen BT; Martelli MP; Récher C; Röllig C; Bornhäuser M; Serve H; Müller-Tidow C; Baldus CD; Haferlach T; Russell N; Falini B
Blood; 2023 Apr; 141(15):1846-1857. PubMed ID: 36508705
[TBL] [Abstract][Full Text] [Related]
30. NPM1 Biology in Myeloid Neoplasia.
Patel SS; Kluk MJ; Weinberg OK
Curr Hematol Malig Rep; 2020 Aug; 15(4):350-359. PubMed ID: 32494951
[TBL] [Abstract][Full Text] [Related]
31. Bone Marrow Clonogenic Myeloid Progenitors from
Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
[TBL] [Abstract][Full Text] [Related]
32. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
Kansal R
Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
[TBL] [Abstract][Full Text] [Related]
33. A Curious Novel Combination of
Venanzi A; Rossi R; Martino G; Annibali O; Avvisati G; Mameli MG; Sportoletti P; Tiacci E; Falini B; Martelli MP
Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573408
[No Abstract] [Full Text] [Related]
34. Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.
Sportoletti P; Varasano E; Rossi R; Mupo A; Tiacci E; Vassiliou G; Martelli MP; Falini B
Leukemia; 2015 Feb; 29(2):269-78. PubMed ID: 25179729
[TBL] [Abstract][Full Text] [Related]
35. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
36. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
37. Mutant NPM1 Maintains the Leukemic State through HOX Expression.
Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA
Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049
[TBL] [Abstract][Full Text] [Related]
38. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.
Federici L; Falini B
Protein Sci; 2013 May; 22(5):545-56. PubMed ID: 23436734
[TBL] [Abstract][Full Text] [Related]
39. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
[TBL] [Abstract][Full Text] [Related]
40. Non-Mutated Nucleophosmin 1 Is Recognized by the CD8+ T Lymphocytes of an AML Patient after the Transplantation of Hematopoietic Stem Cells from an HLA-Haploidentical Donor.
Nemeckova S; Alexova-Zurkova K; Hainz P; Krystofova J; Mackova J; Roubalova K; Stastna-Markova M; Vrana M; Vydra J
Curr Oncol; 2022 Apr; 29(5):2928-2934. PubMed ID: 35621629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
